Farmas USA

SGYP sell the news...muy esperable en este caso. Por eso vendí mi posición swing. De todas formas la tendencia a partir de ahora la veo al alza. Por ello mantengo posición abierta long

NVAX

Magura, no sé si hay un baile de cifras, quedamos que esto subía si pones compra de 6k a 4$, jajaja.
Ahora en serio, suerte con esa venta, que al fin y al cabo también nos viene bien:)

juas Magura, ha sido postearlo y el precio se ha ido a minimos .... si cuando posteas las ordenes de compra el precio hace una cosa ... ahora que toca, lo inverso???? quita esa orden por el amor de diosss!!!! juega en equipo!!!!!

edito: ja,ja, no habia leido a Jose, bueno, no me quiero cebar, lo digo con cariño, eh??? :)))

Con todo el cariño por supuesto, sólo faltaría que a estas alturas no nos conociera todavía:))

CYTX , STEM las células estuvieron animadas ayer y hoy sigue entrando volumen. Que sabes de stem, Ana? hoy a abierto al alza pero busca el cierre de ayer. Podría estar para mirar

NVIV

Tiene sentido. El tipo tiene un accidente y le meten el andamio de células además de realizarse el resto de procedimientos requeridos para que no la palme, pero palma pese a todo y, obviamente, no es achacable a las células. Simplemente informan de que se han quedado sin sujeto de estudio.

Bastante desconectada. STEM estaba vendiendo su propiedad intelectual a finales de año y reduciendo plantilla. CYTX para mí no debería aguantar la subida de ayer, pero si todo sube...

Lo último de CYTX

24-3-2016
independent dmc review from the initial 20 patients of its Phase III STAR trial has been conducted; committee recommends study continue as planned:
Co announced that its Phase III STAR trial has enrolled and treated its 40th patient (50% of target enrollment). In addition, a pre-specified independent data monitoring committee review of safety data from the initial 20 patients has been conducted and the committee has recommended that the study continue as planned.

23-3-2016
Cytori Granted SME Status by European Medicines Agency
http://finance.yahoo.com/news/cytori-granted-sme-status-european-110000624.html

22-2-2016
new data demonstrating a single administration of Cytori Cell Therapy™ (ECCS-50) achieved a sustained improvement in hand dysfunction at two years in patients with scleroderma
• Hand dysfunction assessed by the validated Cochin Hand Function Score (CHFS), showed a 62% reduction in hand dysfunction at two years (p<0.001).
• Raynaud’s Condition Score, a patient-reported measure of the severity and frequency of Raynaud’s Phenomenon, decreased by an average of 89% over baseline at two years (p<0.001).
• Hand pain, as measured by the standard 100mm Visual Acuity Score, and the Scleroderma Health Assessment Questionnaire (SHAQ) score at two years both showed improvement of 50% over baseline (p=0.01 and p<0.001 respectively).
• Improvement of 20 % in grip strength and 330% in pinch strength at two years (p=0.05 and p=0.004 respectively)
• Continued reduction in the number of ulcers from 15 at baseline to 9 at one year and 6 at two years. -> era todo información sabida de agosto
The follow on approval trials, STAR and SCLERADEC II are enrolling, our EU compassionate use (or Managed Access) program has launched and we remain on track to submit to US FDA in mid-2017.”

25-1-2016
its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 20th patient (25% of target enrollment). In addition, as per the trial protocol, an independent data monitoring committee has reviewed safety data from the initial 10 patients and recommended that the study continue as planned.

12-1-2016
entered into an agreement with Idis Managed Access, part of the Clinigen Group plc, to establish a Managed Access Program (MAP) in select countries across Europe, the Middle East, and Africa for patients with impaired hand function due to scleroderma. A MAP will allow Cytori, upon completion of the statutory legal and regulatory requirements, to offer patients and their healthcare providers access to Cytori Cell TherapyTM, known as ECCS-50, in advance of the product’s full marketing authorization in their respective countries

European regulations allow patients access to innovative therapies under development in certain situations, and given the safety profile and promising data thus far for ECCS-50, we think granting limited access is clearly in the best interest of patients with scleroderma of the hand.

ECCS-50 is an autologous, adipose-derived cell therapy produced at the patient’s bedside and administered via a series of hand injections, in a single same-day procedure. ECCS-50 is an investigational product currently in Phase III clinical trials in the U.S. and France

4-1-2016
Empieza reclutamiento fase II en atrofia muscular espinal (SMA)
The primary objective of this double-blind, randomized, placebo-controlled clinical trial is to determine the potential pharmacodynamic effects of a suspension formulation of CK-2127107 following multiple oral doses in patients with Type II, Type III, or Type IV SMA. Secondary objectives are to evaluate the safety, tolerability and pharmacokinetics of CK-2127107. The trial will enroll seventy-two patients in two sequential, ascending dose cohorts (two cohorts of 36 patients each, half ambulatory and half non-ambulatory). Each cohort will be stratified by ambulatory versus non-ambulatory status to receive CK-2127107 dosed twice daily for 8 weeks.
http://ir.cytokinetics.com/phoenix.zhtml?c=142156&p=irol-newsArticle&ID=2125742

ONTY

Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016

http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=965745